CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Ron Cooper

Chief Executive Officer, enGene

Search every verified Ron Cooper interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Ron Cooper, CEO and board member at enGene, discussed the company’s progress and strategy in a podcast recorded at the J.P. Morgan Healthcare Conference. He stated that enGene, a clinical-stage nonviral genetic medicine company, plans to complete its pivotal study this year, read out data, file for approval, and anticipates approval in 2027 for its lead candidate targeting non-muscle invasive bladder cancer. Cooper described organizing the company into two teams, one focused on investor stakeholders and another on business development to support the organization. Cooper also reflected on his previous role as CEO of Albireo Pharma, which he said he scaled from a research organization to a publicly traded commercial biopharma before its acquisition by Ipsen for up to $1.2 billion in 2023. He emphasized the importance of keeping development, financing, and hiring in sync, comparing biotech to a fire requiring science, people, and money. He noted that Wall Street focuses on metrics like complete response rates, but distinguished that role from the company’s mission of bringing drugs to market.

Recent appearances

  • A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer

    February 11, 2026 · 📺 Daniel Levine

    A One‑Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer Non–muscle invasive bladder cancer is a common, slow-progressing form of bladder cancer that makes up a majority of the roughly half a million new cases diagnosed each year. For decades, doctors have relied on a weakened bacterium called BCG, an intravesical immunotherapy, as a standard treatment for early-stage disease, but it fails in about 30 to 40 percent of patients. EnGene is taking a different approach with detalimogene, an experimental, non-viral gene therapy designed to trigger a powerful but localized immune respon…

    Watch on YouTube ↗

  • BoB@JPM: Ron Cooper, enGene

    January 25, 2026 · 📺 Life Science Connect

    On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing ear…

    Watch on YouTube ↗

  • Unveiling Billion-Dollar Trends: AI, Federal Reserve, Biotech & More! Big Biz Show

    August 04, 2025 · 📺 BizTV

    Get ready for another fast-paced episode of the Big Biz Show, hosted from the Loft 100 Studios in sunny Southern California! In this episode, Sully and the team cover key topics in finance, biotech, sales, artificial intelligence, and digital marketing, featuring exclusive interviews and expert panel discussions. Learn how the Federal Reserve works and who can (or can't) fire the Fed Chair with Howie Font. Hear from Ron Cooper, CEO of enGene (NASDAQ: ENGN), about breakthrough innovations in non-muscle invasive bladder cancer, FDA's ARMAT designation, addressable markets, and the company's path…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →